GLP-1 drugs improve heart muscle salvage and infarct size after ST-elevation heart attacks | Research

The takeaway

Scoping review of 10 studies finds exenatide and liraglutide improve myocardial salvage, infarct size, and cardiac function after STEMI, though evidence is limited and larger trials are needed.

Improved myocardial salvage
GLP-1 drugs administered during heart attacks rescued more heart muscle from damage, improved cardiac function, and reduced no-reflow in small studies

What the researchers found

Exenatide: improved infarct size, salvage, cardiac function (mixed results in 2 larger trials). Liraglutide: improved salvage, infarct size, LVEF, stroke volume, reduced no-reflow. Both safe. No significant MACE reduction.

Why it matters

Limiting heart muscle damage during a heart attack directly impacts long-term survival and quality of life. GLP-1 drugs' cardioprotective properties could be a valuable addition to standard STEMI treatment protocols.

How the study worked

Scoping review of 10 studies (RCTs and cohorts) of exenatide and liraglutide in adults with STEMI.

What this study cannot tell us

Small studies with limited generalizability. Mixed results for exenatide. No significant event-driven outcomes. Short follow-up in most studies.

How to read the evidence

Scoping review of small studies. Promising signal but needs large RCT confirmation.

When this study was published

Published in 2025.

The bigger picture

Adding GLP-1 drugs to acute heart attack treatment represents a paradigm shift from pure reperfusion (opening blocked arteries) to active myocardial protection during and after infarction.

Questions still open

Should GLP-1 drugs be given routinely during STEMI?
Which GLP-1 agent and timing provides optimal cardioprotection?
Would larger STEMI trials with GLP-1 drugs show mortality benefit?

Common questions

Can GLP-1 drugs help during a heart attack?

Early evidence suggests yes. When given during or shortly after a heart attack, exenatide and liraglutide helped save more heart muscle from damage and improved heart function. These drugs may add a protective effect on top of standard treatment (opening blocked arteries).

Why would a diabetes drug help during a heart attack?

GLP-1 drugs have anti-inflammatory and metabolic protective effects on heart cells beyond their glucose-lowering properties. During a heart attack, these properties may help protect heart muscle cells from the damage caused by blocked blood flow and the inflammatory response that follows.

Read the original research

The Role of Glucagon-Like Peptide-1 Receptor Agonists in Post ST-Segment Elevation Myocardial Infarction Care: A Scoping Review.

Current epidemiology reports, 12(1), 22

View on PubMed ↗Publisher’s paper ↗

Citation

Soares, Leticia Alves; Paniagua, Cynthia; Nguyen, Julie; Kojic, Ajla; Sanfrey, Elena Rose; Reyome, Madison Emilee; Aguayo, Liliana; Sattler, Elisabeth Lilian Pia. (2025). The Role of Glucagon-Like Peptide-1 Receptor Agonists in Post ST-Segment Elevation Myocardial Infarction Care: A Scoping Review.. Current epidemiology reports, 12(1), 22. https://doi.org/10.1007/s40471-025-00375-5